Literature DB >> 33010951

Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A Comprehensive Meta-analysis.

Abdul A Khan, Muhammad F Khalid, Muhammad T Ayub, Ghulam Murtaza, Rizwan Sardar, Christopher J White, Debabrata Mukherjee, Aravinda Nanjundappa, Timir K Paul.   

Abstract

The presence of concurrent chronic total occlusion (CTO) is a strong predictor for both short-term and long-term mortality. Successful percutaneous coronary intervention (PCI) of CTO has been associated with clinical benefit. We sought to perform a meta-analysis comparing CTO-PCI versus optimal medical therapy. PubMed, ClinicalTrials.gov, Google scholar and the Cochrane Central Register of Controlled Trials were searched for studies published from 2006 to 2019. A total of 16 studies, with 11,314 patients were included. We analyzed data on mortality, cardiac deaths, myocardial re-infarction, major adverse cardiac events, stroke, and repeat CTO-PCI using random-effects models. The odds ratios (OR) with 95% confidence interval (CI) were computed and P < 0.05 was considered as a level of significance. Compared with medical therapy alone, CTO-PCI was associated with lower mortality (OR: 0.45, CI: 0.32-0.63, P < 0.00001) and cardiac deaths (OR: 0.58, CI: 0.38-0.89, P = 0.01). These results were primarily driven by observational studies with no difference observed in randomized controlled trials. There was no significant difference in the incidence of major adverse cardiac events (OR: 0.71, CI: 0.48-1.05, P = 0.54), myocardial re-infarction (OR: 0.71, CI: 0.48-1.05, P = 0.54), stroke (OR: 0.61, CI: 0.32-1.17, P = 0.14, and repeat PCI (OR: 1.28, CI: 0.91-1.78, P = 0.16). This meta-analysis shows lower long-term mortality and cardiac deaths in CTO-PCI group as compared to OMT driven by observational studies with no difference observed in randomized controlled trials. Further randomized trials are needed to confirm these findings and evaluate long term results.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33010951     DOI: 10.1016/j.cpcardiol.2020.100695

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   5.200


  3 in total

1.  Nicorandil Improves Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion.

Authors:  Shaomin Chen; Chen Ma; Xinheng Feng; Ming Cui
Journal:  Front Cardiovasc Med       Date:  2022-05-12

2.  Assessing the Clinical Influence of Chronic Total Occlusions (CTOs) Revascularization and the Impact of Vascularization Completeness on Patients with Left Ventricular (LV) Systolic Dysfunction.

Authors:  Xi Wu; Jie Cai; Qizhou Zhang; He Huang
Journal:  Comput Intell Neurosci       Date:  2022-08-10

Review 3.  Revascularization of chronic total occlusion coronary artery and cardiac regeneration.

Authors:  Ruoxi Liao; Zhihong Li; Qiancheng Wang; Hairuo Lin; Huijun Sun
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.